Allogeneic Stem Cell Transplant for CML in the Gleevec Era: An EBMT Lecture by John Goldman

Posted by rob on June 30, 2004 under Uncategorized | Be the First to Comment

Dr. Goldman stated that Gleevec® has become the initial treatment of choice for newly diagnosed patients with CML since the publication of the IRIS study comparing Gleevec® to interferon and cytarabine.1-3 Current data suggests that:

97% of newly diagnosed patients with CML will achieve a complete hematological remission.
87% will have a major cytogenetic reduction.
76% will have a complete cytogenetic remission following Gleevec® treatment.
Of the 553 patients entered in this trial, 79% are still receiving first-line therapy with Gleevec®.

Dr. Goldman stated that progression-free survival following Gleevec® treatment depends on the log reduction of BCR-ABL. Those with a 3 log reduction have a 100% PFS at 30 months compared to 93% for a 2 log reduction and 81% for a 1 log reduction….

Over the past 4 years, most transplant centers have seen a 50-75% reduction in the number of transplants for chronic phase CML because patients have opted for Gleevec® rather than a transplant.

http://www.cmlwatch.org/modules.php?op=modload&name=News&file=article&sid=908